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Introduction
Ischemia-reperfusion injury (IRI) is inevitable in solid organ transplantation and is a primary cause of activation of innate immune responses (1) . The incidence of IRI is increased due to the use of extended-criteria donors and marginal donors (2) (3) (4) , which often more readily accumulate ischemic injuries. Early intragraft inflammation and activation of innate immunity lead to augmentation of alloimmunity, resulting in increased rates of graft rejection and, ultimately, poorer transplantation outcomes (5) (6) (7) (8) . Improved understanding of underlying mechanisms is critical to the development of targeted therapies to control IRI-induced alloimmunity.
In this study, an observation of early increase in intragraft levels of IL-6 in ischemia prompted us to examine the critical role of allograft-derived dendritic cells (ADDCs) as the potential source of IL-6 responsible for CD4 + alloreactive T cell activity. We examined the importance of autophagy as a survival mechanism for ADDCs under IRI. Induction of autophagy in DCs by starvation markedly increases the production of inflammatory cytokines (9, 10) . However, the impact of IRI on augmenting autophagy in DCs and its implication in alloimmune responses is unknown. Specifically, we examined the importance of key Atg-related protein 5 (Atg5) in the survival of DC under IRI and subsequent production of IL-6. Finally, we developed the first controlled formulation of an anti-IL-6 nanomedicine and an intragraft delivery platform to target the early IL-6-mediated inflammatory responses. We investigated the impact of perfusing organs with nanoparticle (NP)-anti-IL-6 to directly target early innate inflammatory responses within the allograft. This strategy markedly reduced chronic heart allograft rejection, a major barrier to long-term allograft acceptance.
Materials and Methods
Mice C57BL/6, B6.C-H2-Ab1bm12 (BM12) mice were purchased from Jackson Laboratory (Bar Harbor, ME) and used at 6-10 weeks of age. The CD11cCre/Atg5 conditional knockout mice, in which DCs lack Atg5 protein, were provided courtesy of Dr Masaaki Komatsu (Tokyo Metropolitan Institute of Medical Science). All procedures were in compliance with the guidelines for the care and use of laboratory animals at Harvard University, Boston, MA. All protocols were approved by the institutional Animal Care and Use Committee.
Heterotopic cardiac transplantation
Heterotopic intra-abdominal cardiac transplantation was performed by using microsurgical techniques as described previously (11) . Ischemic group hearts were harvested and kept in UW solution for 8 h before transplantation, whereas the control group underwent transplantation within 30 min. Graft heartbeat was evaluated daily via palpation. Rejection was determined as complete cessation of cardiac contractility and was confirmed through direct visualization. For the acute rejection model, donor hearts from C57BL/6 mice were transplanted across complete MHC mismatch into BALB/cJ mice. For the chronic rejection model, we transplanted hearts across one MHC mismatch using C57BL/6 and BM12 as recipients and donors, respectively (12) .
In vivo treatment protocols
For systemic IL-6 blockade, 100 lg anti-mouse IL-6 antibody (courtesy of Genentech) was injected intraperitoneally on days 0-3 and then on alternate days until sacrifice. For studies of locally delivered anti-IL-6, donor hearts were perfused with 100 lg of anti-IL-6 antibody and then transplanted immediately or after 8 h of cold ischemia.
Lymphocyte extraction from transplanted heart grafts
Heart grafts were washed with PBS to remove any remaining clot, minced in RPMI-1640 medium containing 0.1% collagenase, and incubated for 1 hour at 37°C with 5% CO 2 followed by the addition of EDTAcontaining buffers. Cells were then filtered through a 70-lm strainer, counted, and stained for flow cytometric analysis.
DC isolation and culture
Splenic DCs were isolated by using CD11c magnetic beads (Miltenyi Biotec, Cambridge, MA). Bone marrow-derived DCs were generated as described previously (13) . Briefly, femurs and tibiae of C57BL/6 mice were flushed with RPMI-1640 and washed twice with PBS. Then, 3 9 10 6 cells were then plated in a 100-mm 9 20-mm petri dish in RPMI-1640 complete media (containing 10% FCS and 1% L-glutamine and penicillin-streptomycin) supplemented with 20 ng/mL recombinant murine granulocyte-macrophage colony-stimulating factor (R&D Systems). Cells were cultured at 37°C with 5% CO 2 , supplemented with 10 ng/mL recombinant murine granulocyte-macrophage colony-stimulating factor on day 3 and harvested for experiments at day 6.
To simulate ischemia, DCs were harvested and cultured in the presence of different concentrations of H 2 O 2 (Sigma Aldrich, Natick, MA). In some cultures, cells were pretreated with 10 lmol/L Spautin-1 (SML0440; Sigma Aldrich). Subsequently, the cells were washed with complete medium and harvested for experiments.
Flow cytometry
Flow cytometric analysis was performed of graft-infiltrating cells, draining lymph node (DLN), and spleen. For intracellular cytokine staining, cells were stimulated ex vivo with phorbol 12-myristate 13-acetate (50 ng/mL), ionomycin (500 ng/mL), and GolgiStop for 4 h, then permeabilized and stained with fluorochrome-conjugated antibodies against interferon (IFN) c, IL-17, and IL-6. All antibodies were purchased from BD (Becton Dickinson, Franklin Lakes, NJ). Cells were run on a FACSCanto II (BD Biosciences, Franklin Lakes, NJ) instrument. Data were analyzed by using FlowJo software.
Immunohistochemistry and immunofluorescence
Heart grafts were harvested and preserved in Optima Cutting Temperature compound (Tissue-Tek, Torrance, CA) and stored at À80°C. Samples were cut into 5-lm sections, fixed, blocked, and stained with coresponding antibodies. Anti-CD4, CD8, F4/80, and CD11c antibodies were purchased from BD Biosciences. Anti-LC3 and anti-fibronectin antibodies were purchased from Fisher Scientific and Abcam, respectively. Sections were visualized by using a Nikon E-1000 fluorescent microscope.
Lymphocyte infiltration and vascular scoring
Lymphocyte infiltration is graded from 0 to 4 at six random fields of each hematoxylin-eosin-stained cardiac section by two researchers (six sections per heart, three mice per group). The grades are defined as follows: grade 0 (no lymphocyte infiltration), grade 1 (<25% lymphocyte infiltration), grade 2 (25-50% lymphocyte infiltration), grade 3 (50-75% lymphocyte infiltration), and grade 4 (>75% lymphocyte infiltration and myocyte hemorrhage).
Vascular score is determined by a combination of vascular occlusion score and perivascular lymphocyte infiltration. Vascular occlusion is scored from grade 0 to 4 for every vessel (six sections per heart, three mice per group). The grades are defined as follows: grade 0 (no occlusion), grade 1 (<50% occlusion), grade 2 (50-75% occlusion), grade 3 (75-95% occlusion), and grade 4 (>95% occlusion). The perivascular lymphocyte infiltration is scored as mentioned earlier and then was added to the vascular occlusion score.
Mitochondrial staining
Mitochondrial staining was performed on splenic DCs isolated with CD11c magnetic beads (Miltenyi Biotec) by using 100 nmol/L Mitochondrial Membrane Potential Assay Kit (Abcam) in PBS for 30 min. Cells were then washed, mounting media containing DAPI was added, and the slides were prepared. Images were taken by using a Nikon E-1000 fluorescent microscope.
LC3-RFP lentivirus transfection and live imaging
LC3-RFP viruses were generated by transfecting 293T cells. Media containing virus particles were collected at 48 and 72 h. For transduction of primary cultured bone marrow-derived DCs, lentiviral particles were purified via ultracentrifugation of supernatants at 24 000 rpm in a Beckman SW40 Ti rotor. Live cell imaging experiments were carried out on a Nikon Eclipse Ti inverted microscope in a humidified chamber and 5% CO 2 .
Engineering and characterization of poly(lactic-co-glycolic acid)-based nanocarriers of anti-IL-6
Poly(lactic-co-glycolic acid) (PLGA, 50:50 lactic acid:glycolic acid [w:w]) nanoparticles loaded with anti-IL-6 antibody were fabricated using a double emulsion-solvent evaporation method. First, 10 lg of PEG (polyethylene glycol)-PLGA (50:50) was dissolved in 1 mL of ethyl acetate. Then aqueous solution of anti-IL-6 (1 mg/mL) was mixed with PEG-PLGA solution using probe sonication for 10 s over ice. Immediately, the first emulsion was transferred into 2 mL of poly(vinyl alcohol) solution (0.5% w/v) and emulsified using probe sonication in three 10-s bursts (40% amplitude). The solution was allowed to cool in an ice bath between each burst. The final emulsion was added into 50 mL deionized water and stirred for 2 h to evaporate the solvent and harden the nanoparticles. The anti-IL-6-loaded PLGA nanoparticles (NP-anti-IL-6) were collected and washed via centrifugation by using Amicon Ultra-15 centrifugal filter units (MWCO 100 kDa) at 3000 9 g for 10 min. The size of the nanoparticles was then characterized by using dynamic light scattering and transmission electron microscopy. The concentration of the anti-IL-6 loaded into PLGA particles was assessed by measuring absorbance of the supernatant after each washing step at k = 266 nm and comparing it with a calibration curve of the absorbance of various concentrations of anti-IL-6 at 266 nm.
Quantitative RT-PCR
Harvested cardiac grafts were flash frozen in liquid nitrogen and used for RNA extraction. Tissues were homogenized and sonicated, and RNA was isolated by using RNeasy mini kit (Qiagen, Valencia, CA). Harvested RNA was subsequently measured and used to prepare cDNA with use of an iScript cDNA synthesis kit (Bio-Rad Laboratories, Inc., Hercules, CA). Quantitative PCR was then performed for IL-6, Atg5, Atg12, Beclin1, DEEP, and MAP-L3B genes. Expression was assessed compared with GAPDH expression. Relative gene expression was calculated by using the 2 DDCT method.
Statistics
Kaplan-Meier survival graphs were constructed, and log rank comparison of the groups was used to calculate p-values for survival comparisons between various groups. Data analysis was performed by using GraphPad Prism (GraphPad Software, Inc., San Diego, CA). Differences between groups were evaluated by Student t-test or ANOVA to determine significance. p < 0.05 was considered a significant difference.
Results

Ischemia increases autophagy in DCs
While increased autophagy due to stress (i.e. starvation) markedly increases DC production of inflammatory cytokines (9, 10) , the impact of IRI on the metabolic programming and induction of autophagy in DCs remains to be explored. Oxidative stress has been shown to contribute to the decline in mitochondrial function and autophagy-related pathology in aging (14, 15) .
We first examined the effect of oxidative stress on DC mitochondria in vitro by using H 2 O 2 exposure as a model of DC ischemia as described previously (13, (16) (17) (18) (19) (20) . Control and oxidatively stressed DCs (OS-DCs) were stained with mitotracker red, which stains mitochondrial membrane potential. Immunofluorescent cell imaging revealed lower mitochondrial membrane potential in OSDCs compared with untreated DCs ( Figure 1A ).
We then examined the impact of oxidative stress on the induction of autophagy in DCs in vitro. By using immunofluorescence staining for Atg5, an ubiquitin ligase necessary for autophagosome elongation, our data demonstrated increased autophagosome formation in OS-DCs compared with controls ( Figure 1B ). OS-DCs and control DCs transfected with LC3-RFP lentivirus were studied for autophagosome formation by using immunofluorescence microscopy.
We noted significant upregulation of autophagy in OS-DCs as shown by an increase in the membranous form of LC3 protein, resulting in dense localized RFP with increased signal intensity ( Figure 1C ).
We next examined the expression of major autophagy genes by quantitative PCR on mRNA from splenic DCs. OS-DCs had significantly higher expression of autophagyrelated genes, including Atg5, Atg12, MAP L3B, and DEEP, compared with control DCs (n = 3 samples per group) ( Figure 1D ).
We previously have shown that IRI increases production of IL-6 by ischemic DCs (13) . We next studied the effect of autophagy on IL-6 production from DCs. OS-DCs and DCs were treated with Spautin-1, an autophagy inhibitor. Increased levels of IL-6 were present in culture media from OS-DCs compared with control, as measured by Luminex assay. However, blocking autophagy markedly reduced IL-6 production by OS-DCs ( Figure 1E ).
To study the role of DC Atg5 in increased IL-6 production under IRI in vivo, ischemic hearts from wild-type (WT) C57BL/6 and CD11cCre/Atg5 conditional knockout donors were transplanted into BALB/cJ recipients. CD11cCre/Atg5 conditional knockout mice lack Atg5 protein exclusively in their DCs. Grafts were harvested at day 1 posttransplantation, mRNA was isolated, and relative IL-6 gene expression was studied. Our data reveal markedly reduced IL-6 expression in ischemic grafts with Atg5-deficient DCs compared with WT grafts (n = 3 mice/group, *p < 0.05) ( Figure 1F ). Although cell death subsequent to inhibition of autophagy has contributed to less IL-6 production (second column), the remainder of live cells did not increase IL-6 production in response to ischemic injury. (F) Heart allografts from ischemic WT and CD11cCre/Atg5 conditional knockouts were transplanted into BALB/cJ recipients. Hearts were harvested at day 1 posttransplantation and studied for IL-6 gene expression. Heart grafts with Atg5-deficient DCs showed markedly lower expression of IL-6 compared with WT grafts (n = 3 mice/group, *p < 0.05). [Color figure can be viewed at wileyonlinelibrary.com]
Atg5 plays a key role in the survival of DCs under IRI To assess the mechanism of decreased IL-6 expression in ischemic grafts with Atg5 À/À DCs, we isolated splenic DCs from WT C57BL/6 and CD11cCre/Atg5 conditional knockout mice and exposed them to H 2 O 2 in vitro. DCs were then harvested and studied for cell death rate by using flow cytometry. Our data demonstrate significantly lower survival rate in autophagy-deficient DCs compared with WT DCs under ischemic conditions (Figure 2A) .
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We then studied the effect of Atg5 deficiency in ADDC on their survival in vivo. Ischemic hearts from either CD11cCre/Atg5 conditional knockout or WT C57BL/6 donors were transplanted into BALB/cJ recipients. Grafts were harvested on day 1 posttransplantation. Graftinfiltrating cells were analyzed by flow cytometry to compare rate of death in CD11c + DCs. ADDCs deficient in Atg5 showed markedly increased apoptosis compared with their WT controls ( Figure 2B ). These results emphasize the role of autophagy in DC survival under ischemia and subsequent IL-6 production.
IRI markedly induces DC autophagy and worsens chronic rejection
We then examined the impact of IRI on the development of chronic rejection, a major obstacle to long-term success in solid organ transplantation (21) . Hearts from H2-Ab1bm12 (BM12) mice were transplanted into C57BL/6 mice, a single MHC class II mismatch model (22, 23) . On day 14 posttransplantation, ischemic grafts showed marked cell infiltration, increased myocyte injury, vascular occlusion, and graft muscle necrosis compared with controls ( Figure 3 , A5 and A6 compared with A1 and A2). Fibronectin, a marker of tissue fibrosis, was increased in the ischemic grafts compared with controls ( Figure 3 , A7 compared with A3). There was a significant increase in F4/80 + macrophages in ischemic grafts compared with controls ( Figure 3 , A8 compared with A4).
We then examined the expression of autophagy genes in control and ischemic heart grafts harvested at day 14. We observed a marked increase in expression of ischemic conditions, we found not only increased LC3 expression, which is a marker of autophagy, but also its colocalization with CD11c + DCs ( Figure 3C , right panel).
To study the effect of ADDC autophagy on chronic rejection, we transplanted ischemic hearts from either WT or CD11cCre/Atg5 conditional knockout mice into BM12 recipients. Hearts were harvested 28 days posttransplantation and examined for severity of chronic rejection. CD11cCre/Atg5 conditional knockout hearts revealed lower tissue lymphocyte infiltration, vasculopathy, and less macrophage infiltration by histology (Figure 3D) . Significantly less lymphocyte infiltration and vasculopathy were seen in CD11cCre/Atg5 conditional knockout grafts compared with controls ( Figure 3E , n = 3/each). At the same time, we did not observe differences in the percentage of regulatory T or effector cells (CD44 high CD62 low ) in the spleen or DLN of allograft recipients (data not shown).
Intraorgan delivery of anti-IL-6 therapy significantly decreases chronic rejection induced by IRI As a potential therapeutic target, we then investigated the role of anti-IL-6 in reducing IRI-induced chronic rejection. C57BL/6 recipients of BM12 heart grafts with 8 h ischemia were treated with 100 lg systemic (intraperitoneal) anti-IL-6 antibody injections on days 0-3, followed by every other day injection until day 13 posttransplantation. Heart grafts were harvested on day 14 and examined for chronic rejection. Compared with untreated ischemic grafts, heart allografts from systemic anti-IL-6-treated ischemic graft showed significantly less cell infiltration and vascular injury (Figure 4 , D1 and D2, compared with Figure 3 , A5 and A6). Systemic anti-IL-6 treatment significantly suppressed macrophage infiltration in the ischemic grafts to a level comparable to nonischemic controls (Figure 4 , D3 compared with Figure 3 , A4). Our findings suggest that systemic anti-IL-6 therapy abrogates the effect of ischemia in the progression of chronic allograft rejection.
Similar to other immunomodulatory agents, systemic anti-IL-6 therapy is associated with risks (e.g. infection) (24) . Given the importance of intragraft IL-6 expression in IRI-mediated rejection, we hypothesized that local delivery of anti-IL-6 might be a useful alternative strategy. Heart grafts harvested from BM12 donors were perfused with 100 lg of anti-IL-6 and kept in UW solution for 8 h (ischemia plus local anti-IL-6). Interestingly, a single dose of local intragraft treatment (nine times lower than systemic dose) significantly protected ischemic grafts from chronic rejection as demonstrated by a reduction in inflammatory cell infiltrates, macrophage infiltration, and vascular injury (Figure 4, D4-6 ). Quantification of cell and vascular injuries in both groups is shown in Figures 4B and 4C . Our data indicate that intraorgan delivery of anti-IL-6 confers significant protection against chronic rejection with significantly less systemic exposure to anti-IL-6.
Double emulsion assembly and characterization of NP-anti-IL-6
We then tested the hypothesis that perfusing the organ with NP-anti-IL-6 allows for more effective control of intragraft inflammatory responses with sustained release of anti-IL-6. We also tested whether we could reduce anti-IL-6 dosing by using such a platform. Moreover, direct delivery of NP-anti-IL-6 to the organ before transplantation would reduce the accumulation of NPs in nontargeted organs.
We encapsulated anti-IL-6 in PLGA-NPs by dispersing the hydrophilic anti-IL-6 in an immiscible PLGA solution using probe-sonication followed by a second emulsification in an aqueous solution. This technique provides first NP-anti-IL-6 with controlled size and narrow size distribution depending on the probe-sonication power and time. Figure 5A is a transmission electron microscopic image of NP-anti-IL-6, showing that particles are spherical in shape and range in size from 50 to 200 nm, the majority of which are 100 nm in diameter ( Figure 5B ).
To test the efficiency of NP-anti-IL-6 in retaining and releasing anti-IL-6 in vitro, NP-anti-IL-6 and free anti-IL-6 were added to a T cell proliferation assay. Significant suppression of T cell proliferation by both free anti-IL-6 and NP-anti-IL-6 was noted compared with untreated stimulated T cells. However, there was no statistical difference between free anti-IL-6 or particle-embedded anti-IL-6 antibody in the level of inhibition of T cell proliferation in vitro ( Figure 5C ).
Delivery of NP-anti-IL-6 to the organ before transplantation reduces chronic rejection To confirm tissue accumulation of NP, we perfused hearts before transplantation with NP labeled with rhodamine and grafts were harvested at day 7. Compared with control unperfused hearts, rhodamine-labeled NPs (red) were detected in treated grafts ( Figure 5D ). We next sought to examine the efficacy of localized delivery of NP-anti-IL-6 in suppressing chronic rejection. Ischemic heart grafts harvested from BM12 donors were perfused with NP-anti-IL-6 (equivalent of 4 lg anti-IL-6 antibody), transplanted into C57BL/6 recipients, and harvested on day 14. Ischemic grafts perfused with NP-anti-IL-6 showed minimal cellular infiltration and almost no tissue necrosis, vascular infiltration, or occlusion compared with ischemia controls (Figure 5E left) . We further phenotyped graft-infiltrating cells, which showed decreased frequency of CD3 + and F4/80 + infiltrating cells ( Figure 5E , middle and right). Interestingly, despite the marked histological differences, FACS analysis of spleen and DLN of recipient mice did not reveal discernable differences in the percentage of regulatory or effector T cells (CD44 high CD62 l low T cells) (data not shown). 
Discussion
IRI is an inevitable complication of solid organ transplantation and a major source of intragraft inflammation and innate immune activation; as such, targeting this process holds great potential to improve transplantation outcomes (25) (26) (27) (28) .
IL-6 has been shown to promote allograft rejection in a number of studies (29) (30) (31) (32) . However, the role of IRIinduced autophagy in ADDCs as the mechanism of induction of IL-6 production by ADDCs resulting in the augmentation of alloimmunity has not been previously explored.
ADDCs are readily activated by danger molecules and reactive oxygen species produced within the graft in the setting of ischemia (13, 25) . Autophagy is a cellular process involved in degradation of damaged intracellular organelles and has been shown to enhance DC antigen presentation, maturity, production of inflammatory cytokines, and CD4 + T cell priming (9, (33) (34) (35) (36) . Previous studies have shown elevated levels of autophagy in several cell types as a result of H 2 O 2 exposure (37-41). While autophagy has been shown to play a role in T cell homeostasis and cytokine production and, therefore, also affects allograft survival (42, 43) , its roles in upregulating ADDC functions and augmenting alloimmune responses are unclear. We demonstrated higher autophagy levels in OS-DCs by using quantitative PCR and immunofluorescence for Atg5 and following lentiviral transfection of DCs with fluorescent-labeled LC3 gene in vitro. Interestingly, while OSDCs showed increased IL-6 production, blocking autophagy reduced the production of IL-6. Mitochondrial damage in OS-DCs has been reported to increase autophagy (44, 45) . Damaged mitochondria can contribute to further injury and disruption of cell function via the generation of more reactive oxygen species (37) . Our data indicate that IRI also causes reduced mitochondrial membrane potential in DCs. Using CD11cCre/Atg5 conditional knockout donors, we showed that lack of Atg5 in DCs results in an increased death rate after ischemia. Using hearts from CD11cCre/Atg5 conditional knockout donors reduced the severity of chronic rejection compared with controls.
While animal studies have highlighted the importance of targeting IL-6 to promote allograft survival (29, 30, 32, (46) (47) (48) (49) (50) , the impact of anti-IL-6 in reducing IRI-induced alloimmunity has not been shown previously. Our data indicate that anti-IL-6 treatment abrogates this effect of IRI. Immune manipulation of organs before transplantation represents a highly innovative, significant, and feasible approach in transplantation. Before transplantation, there is a unique opportunity to apply treatments directly to the organ. In addition to increasing the efficacy, local delivery also allows reduced systemic exposure to anti-IL-6, which carries risks of infectious and other complications related to systemic immunosuppression (24) .
Given the pleotropic functions of IL-6 as an inflammatory and regulatory cytokine, the impact of anti-IL-6 in IRIinduced alloimmunity could be complex. IL-6 has been shown to have both deleterious and beneficial effects in nontransplant IRI models (51) (52) (53) (54) (55) (56) . These differential results might be due to the differences in the timing of injury, type of IRI model, and interventions applied. Nonetheless, numerous studies have highlighted the transplanted organ as the source of IL-6 production, which supports the concept of targeting these pathways within the allograft. Moving forward, it would be important to carry out kinetic studies of the release of anti-IL-6 and examine the potential effects of anti-IL-6 on various cardiac cell types including the metabolism of cardiomyocytes and their contractility over time posttransplantation.
Targeted delivery of immune regulatory agents to the organ not only suppresses local alloreactive T cells involved in rejection but also prevents alloreactive T cell priming (57) (58) (59) (60) . Ischemic cardiac allografts perfused with free anti-IL-6 antibody showed significantly suppressed chronic rejection. With increased control and characterization of materials at the nanoscale size, the field of nanotechnology has spurred a high level of interest in medicine, particularly in oncology (61) , but has also increasingly received attention for application in transplantation (62) (63) (64) . We therefore assessed whether nanodelivery, with sustained-release capacity of anti-IL-6 within the organ improves the efficacy of local delivery of anti-IL-6. We used FDA-approved biodegradable polymeric PLGA-NPs with controlled-release capacity for anti-IL-6. We engineered an NP carrier of anti-IL-6 with excellent loading and release capacity for organ delivery. Using NP-anti-IL-6, we were able to significantly reduce chronic rejection, with a dose that is >200 times lower than that of systemic anti-IL-6 (total of 4 lg anti-IL-6 in NP vs. 900 lg systemic). This is the first controlled formulation of an anti-IL-6 nanomedicine, which holds the potential to shape future immunosuppressive therapies in transplantation. Interestingly, we did not observe an effect on regulatory or effector T cells in the periphery, emphasizing the lack of systemic immunosuppression. This also suggests that local IL-6 production is a central contributor to the development of chronic rejection in a model of allograft ischemia. However, given that we used clinically relevant polyclonal models, changes in the regulatory or effector T cell compartments may be less readily identified. Alloantigen-specific transplant models may be useful to examine this in greater detail in future studies. Here, our primary aim was to use clinically relevant models to generate translational data, focused on chronic rejection, which remains the most important barrier to long-term graft survival. Our ultimate goal is to develop a translational combinatorial targeted-delivery technology for immunoregulatory molecules with broad clinical applicability.
In summary, our study indicates that IRI increases DC autophagy and production of IL-6, enhancing chronic rejection. Delivering anti-IL-6 to organs before transplantation via NPs represents a highly innovative strategy with significant clinical implications.
